Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 21;12(3):345.
doi: 10.3390/v12030345.

Non-Coding RNAs and Their Role in Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Infections

Affiliations
Review

Non-Coding RNAs and Their Role in Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Infections

Wenzhe Wu et al. Viruses. .

Abstract

Recent high-throughput sequencing revealed that only 2% of the transcribed human genome codes for proteins, while the majority of transcriptional products are non-coding RNAs (ncRNAs). Herein, we review the current knowledge regarding ncRNAs, both host- and virus-derived, and their role in respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. RSV is known as the most common cause of lower respiratory tract infection (LRTI) in children, while hMPV is also a significant contributor to LRTI in the pediatrics population. Although RSV and hMPV are close members, belonging to the Pneumoviridae family, they induce distinct changes in the ncRNA profile. Several types of host ncRNAs, including long ncRNA (lncRNA), microRNAs (miRNAs), and transfer RNA (tRNA)-derived RNA fragments (tRFs), are involved as playing roles in RSV and/or hMPV infection. Given the importance of ncRNAs in regulating the expression and functions of genes and proteins, comprehensively understanding the roles of ncRNAs in RSV/hMPV infection could shed light upon the disease mechanisms of RSV and hMPV, potentially providing insights into the development of prevention strategies and antiviral therapy. The presence of viral-derived RNAs and the potential of using ncRNAs as diagnostic biomarkers are also discussed in this review.

Keywords: RSV; hMPV; ncRNAs.

PubMed Disclaimer

Conflict of interest statement

All authors concur there are no conflicts of interest associated with this published work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic diagram of the respiratory syncytial virus (RSV)-mediated microRNAs (miRNAs)-messenger RNA (mRNA) interaction networks involved in inflammatory responses. The RSV-increased miRNAs are indicated in red, the decreased miRNAs by RSV are shown in green. Arrows mark the positive effects between elements, whereas stop bars denote inhibitory effects.
Figure 2
Figure 2
Schematic diagram of the effect of RSV-regulated miRNAs on cell survival. RSV-induced and -decreased miRNAs are indicated in red and green, respectively. Arrows mark and stop bars respectively denote the positive and negative effects on the downstream molecules.
Figure 3
Figure 3
Biogenesis and classification of transfer RNA (tRNA)-derived RNA fragments (tRFs). The tRFs are generally classified into tRF-1 series, tRF-3 series, and tRF-5 series. tRF-1 series are usually those from the 3′-trailer sequences of pre-tRNA. tRF-3 and tRF-5 series are those whose sequences aligned to the 3′- and 5′- end of the mature tRNAs respectively; The length of tRFs ranges from 18 to 40 nt.
Figure 4
Figure 4
Model on the molecular mechanism used by tRF5-GluCTC to promote RSV replication. RSV infection induces tRF5-GluCTC, which targets APOER2 and suppresses its expression. APOER2 is an antiviral protein carrying out its antiviral role via its sequestration of the P protein of RSV. Therefore, the decreased expression of APOER2 frees more P proteins and makes them more available to form RdRp with other viral proteins.

Similar articles

Cited by

References

    1. Collaborators G.B.D.L.R.I. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 2018;18:1191–1210. - PMC - PubMed
    1. Peter F., Wright F.T.C. Generic Protocol to Examine the Incidence of Lower Respiratory Infection due to Respiratory Syncytial Virus in Children Less Than Five Years of Age. World Health Organization, Department of Vaccines and Biologicals; Geneva, Switzerland: 2000.
    1. Schauer U., Hoffjan S., Bittscheidt J., Kochling A., Hemmis S., Bongartz S., Stephan V. RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur. Respir. J. 2002;20:1277–1283. doi: 10.1183/09031936.02.00019902. - DOI - PubMed
    1. Henderson J., Hilliard T.N., Sherriff A., Stalker D., Al Shammari N., Thomas H.M. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16:386–392. doi: 10.1111/j.1399-3038.2005.00298.x. - DOI - PubMed
    1. Sigurs N., Gustafsson P.M., Bjarnason R., Lundberg F., Schmidt S., Sigurbergsson F., Kjellman B. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 2005;171:137–141. doi: 10.1164/rccm.200406-730OC. - DOI - PubMed

Publication types

MeSH terms